Prediabetic State Clinical Trial
— TIMEDOfficial title:
Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors
Exercise is well-known to improve skeletal muscle energy metabolism and is an established intervention to improve muscle insulin sensitivity and to counter the development of type 2 diabetes (T2D). However, given the 24h rhythmicity in substrate metabolism previously observed in healthy, lean men and the lack of such rhythmicity in men with insulin-resistance, the investigator hypothesize that appropriate timing of exercise training can maximize the metabolic health effects of exercise. Indeed, a preliminary study in humans revealed that afternoon high-intensity interval training (HIIT) exercise was more effective than morning exercise in improving 24h blood glucose levels in men with T2D. Another recent study in mice showed that the time of day is a critical factor in augmenting the beneficial effects of exercise on the skeletal muscle metabolome as well as on whole-body energy homeostasis. However, human studies that specifically target the impact of timing of exercise training on glucose homeostasis and metabolic health are scarce and the potential underlying mechanisms largely unknown. The overarching goals of this project is to improve 24-hour rhythmicity of metabolism in men and women with prediabtes by appropriate timing of exercise and to assess its effect on metabolic health and immune response. Acute and prolonged exercise interventions timed in the morning vs late afternoon will be carried out in individuals with prediabetes to determine whether acute exercise in the afternoon and prolonged exercise training in the afternoon can improve peripheral insulin sensitivity, compared to exercise in the morning, and positively affect adipose tissue dietary fatty acid storage and partitioning of dietary fatty acids in skeletal muscles.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | April 30, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years to 75 Years |
Eligibility | Inclusion Criteria: - Pre-diabetes: - Fasting plasma glucose: 6.1 to 6.9 mmol/L or - 2-hour plasma glucose post 75g OGTT: 7.8 to 11.0 mmol/L and - HbA1c: 6.0 to 6.4% - or Insulin resistant: glucose clearance rate = 360 ml/kg/min as determined using the Oral Glucose Insulin Sensitivity Index at Time 120 min. - BMI > 25 kg/m2 - To be willing and able to adhere to the specifications of the protocol; - To have signed an informed consent document indicating that they understood the purpose of and procedures required for the study and were willing to participate in the study. Exclusion Criteria: - overt cardiovascular disease as assessed by medical history, physical exam, and abnormal ECG - Treatment with any drug known to affect lipid or carbohydrate metabolism, except statins (to be stopped 3 weeks prior to study A), metformin or anti-hypertensive drugs (to be stopped 7 days prior to the studies); - presence of liver or renal disease other than uncomplicated NASH or mild isolated proteinuria; uncontrolled thyroid disorder; - Uncontrolled severe hypertension, systolic pressure = 180 mm Hg or diastolic pressure = 110 mm Hg; - History of ischemic heart disease, tachyarrhythmia, QT interval prolongation, risk factors for torsade de pointes (eg hypokalemia), or taking any medication known to prolong the QT interval; - History of serious gastrointestinal disorders (malabsorption, peptic ulcer, gastroesophageal reflux requiring surgery, etc.); - Presence of a pacemaker; - Having undergone a PET study or CT scan in the past year; - Any contraindication to stopping statins for 3 months and stopping an anti-hypertensive medication and metformin for 7 days; - smoking (>1 cigarette/day) and/or consumption of >2 alcoholic beverages per day; - No blood donation two month prior the study; - prior history or current fasting plasma cholesterol level > 7 mmol/l or fasting TG > 6 mmol/l. |
Country | Name | City | State |
---|---|---|---|
Canada | Centre de recherche du CHUS | Sherbrooke | Quebec |
Lead Sponsor | Collaborator |
---|---|
Université de Sherbrooke | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Laval University, Leiden University Medical Center, Maastricht University Medical Center, McMaster University, University of Calgary, University of Waterloo, Wageningen University |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Adipose tissue dietary fatty acid (DFA) partitioning | Determined using oral administration of [18F]-Fluoro-6-Thia-Heptadecanoic Acid (FTHA) during whole-body acquisition | Measured 180 minutes, 240 minutes, 300 minutes and 360 minutes after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). | |
Primary | Change in lean organ (heart, liver, skeletal muscle) DFA partitioning | Determined using oral administration of [18F]-Fluoro-6-Thia-Heptadecanoic Acid (FTHA) during whole-body acquisition | Measured 180 minutes, 240 minutes, 300 minutes and 360 minutes after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). | |
Primary | Change in skeletal muscle ATP fluxes in vivo | Determined using phosphorus-31 magnetic resonance spectroscopy. | Measured 170 minutes before and 30 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). | |
Primary | Change in glucose control. | Determined using continuous glucose monitoring and repeated blood samples obtained during metabolic visit. | Measured continuously 2-3 days before and 2-3 days after first and final exercise session, after 12-week exercise intervention. | |
Secondary | Change in adipose tissue nonesterified fatty acid (NEFA) metabolism. | Determined using [11C]-palmitate with dynamic PET acquisition | Measured 150 minutes before and 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). | |
Secondary | Change in lean organ (heart, liver, skeletal muscle) NEFA metabolism. | Determined using [11C]-palmitate with dynamic PET acquisition | Measured 150 minutes before and 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). | |
Secondary | Change in insulin sensitivity | Determined by measuring circulating glucose, NEFA, insulin and C-peptide following the liquid meal. | Measured every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). | |
Secondary | Change in dietary fatty acid oxidation | Determined by measuring breath [13C]-carbon dioxide enrichment. | Measured every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). | |
Secondary | Change in total substrate utilisation | Determined using indirect calorimetry | Measured every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). | |
Secondary | Change in postprandial plasma NEFA turnover. | Determined using continuous infusion of [7,7,8,8-2H]-palmitate. | Blood sample collected every 60 min following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). | |
Secondary | Change in postprandial plasma glucose turnover | Determined using continuous infusion of [1-3H]-glucose | Blood sample collected every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). | |
Secondary | Change in left ventricular function by Positron Emitting Positron (PET) ventriculography | Determined using [11C]-palmitate combined with ECG-gated cardiac dynamic PET acquisition. | Measured 150 minutes before and 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). | |
Secondary | Change in plasma distribution of DFA metabolites | Determined using oral administration of [18F]-FTHA to quantify the incorporation of 18F-labeled fatty acids given with the liquid meal, into triglyceride-rich lipoproteins and NEFA. | Blood sample collected every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). | |
Secondary | Change in composition and activation status of immune cell subsets | Determined by extensive Fluorescence Activated cell Sorting (FACS) analysis | Blood sample collected before and after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). | |
Secondary | Change in plasma cytokine levels | Determined by ELISA | Blood sample collected before and after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05424107 -
A Mediterranean Intervention on Prediabetic Children
|
N/A | |
Recruiting |
NCT02681887 -
Effect of Melatonin on Cardiometabolic Risk- FULL
|
Phase 3 | |
Completed |
NCT04088461 -
Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine
|
Phase 4 | |
Recruiting |
NCT02561377 -
Effect of Resistance Training on Metabolic Control and Outcome in Prediabetes (NMR-based Metabonomics)
|
N/A | |
Completed |
NCT02551640 -
Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients
|
N/A | |
Completed |
NCT02678390 -
Medium Chain Triglycerides and Aerobic Exercise on Ketone Production in Women With or Without Prediabetes
|
N/A | |
Completed |
NCT02459691 -
Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos)
|
N/A | |
Completed |
NCT01671293 -
Multicomponent Telecare Model for Supporting Prediabetes Patients
|
N/A | |
Completed |
NCT01479933 -
Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes
|
N/A | |
Completed |
NCT00960973 -
The Effect of Vitamin K Supplementation on Glucose Metabolism
|
Phase 4 | |
Completed |
NCT00455325 -
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
|
Phase 2 | |
Recruiting |
NCT05340868 -
Genetics of the Acute Response to Oral Semaglutide
|
N/A | |
Recruiting |
NCT04984421 -
IMplementation of the Family Support PRogramme A Healthy School Start to Prevent OVErweight and Obesity (IMPROVE)
|
N/A | |
Recruiting |
NCT04131582 -
Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes
|
Phase 3 | |
Recruiting |
NCT04134650 -
Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes
|
Phase 3 | |
Recruiting |
NCT05347030 -
Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population
|
N/A | |
Completed |
NCT04074148 -
Effectiveness of Diabetes Prevention Education Program on Diabetes Prevention Among Prediabetes Population in Nepal
|
N/A | |
Recruiting |
NCT05050266 -
Enhancing Mental and Physical Health of Women Veterans
|
N/A | |
Completed |
NCT02684565 -
Effects of Branch Chain Amino Acids on Glucose Tolerance in Obese Pre-Diabetic Subjects
|
N/A | |
Completed |
NCT01956929 -
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.
|
Phase 1 |